- Home
- UPLD vs ACET Comparison
UPLD vs ACET Comparison
Compare UPLD & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPLD
- ACET
- Stock Information
- Founded
- UPLD 2010
- ACET 1947
- Country
- UPLD United States
- ACET United States
- Employees
- UPLD N/A
- ACET N/A
- Industry
- UPLD Computer Software: Prepackaged Software
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- UPLD Technology
- ACET Health Care
- Exchange
- UPLD Nasdaq
- ACET Nasdaq
- Market Cap
- UPLD 51.0M
- ACET 60.5M
- IPO Year
- UPLD 2014
- ACET N/A
- Fundamental
- Price
- UPLD $2.81
- ACET $0.76
- Analyst Decision
- UPLD Strong Buy
- ACET Strong Buy
- Analyst Count
- UPLD 1
- ACET 7
- Target Price
- UPLD $4.50
- ACET $5.60
- AVG Volume (30 Days)
- UPLD 897.5K
- ACET 682.2K
- Earning Date
- UPLD 07-31-2025
- ACET 08-07-2025
- Dividend Yield
- UPLD N/A
- ACET N/A
- EPS Growth
- UPLD N/A
- ACET N/A
- EPS
- UPLD N/A
- ACET N/A
- Revenue
- UPLD $251,757,000.00
- ACET N/A
- Revenue This Year
- UPLD N/A
- ACET N/A
- Revenue Next Year
- UPLD N/A
- ACET N/A
- P/E Ratio
- UPLD N/A
- ACET N/A
- Revenue Growth
- UPLD N/A
- ACET N/A
- 52 Week Low
- UPLD $1.69
- ACET $0.45
- 52 Week High
- UPLD $5.64
- ACET $1.63
- Technical
- Relative Strength Index (RSI)
- UPLD 64.99
- ACET 57.17
- Support Level
- UPLD $2.63
- ACET $0.64
- Resistance Level
- UPLD $3.17
- ACET $0.75
- Average True Range (ATR)
- UPLD 0.37
- ACET 0.06
- MACD
- UPLD 0.09
- ACET 0.01
- Stochastic Oscillator
- UPLD 49.31
- ACET 94.81
About UPLD Upland Software Inc.
Upland Software Inc is a software company. It provides cloud-based software applications in three categories: Knowledge Management that provides solutions designed to help organizations capture, organize, and distribute information to employees and customers. Content Lifecycle and Workflow Automation offers solutions that support document management, compliance, and process efficiency across various industries. Digital Marketing solutions that provides tools for audience engagement, campaign management, and content distribution across digital channels.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.